MiNK appoints former HHS ASPR Robert Kadlec to board

MiNK Therapeutics, Inc.

Dr. Robert Kadlec elected Class II director effective Oct. 30, 2024; term expires at 2026 annual meeting.
Previously served as HHS Assistant Secretary for Preparedness and Response and co-conceived Operation Warp Speed.
Will serve on Corporate Governance and Nominating Committee; granted option for 41,745 shares vesting over 3 years.
Expertise in biodefense and pandemic preparedness aligns with MiNK's iNKT cell therapy focus on ARDS and infectious diseases.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Robert Kadlec

Director

INKT · MiNK Therapeutics, Inc.

Effective: 2024-10-30
Filed: October 31, 2024, 7:59 PM ET

On October 30, 2024, the Board of Directors (the “Board”) of MiNK Therapeutics Inc., ("MiNK") elected Dr. Robert Kadlec to become a Class II director of MiNK with an initial term that expires at MiNK's annual meeting of stockholders in 2026.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Robert Kadlec was elected as Director at MiNK Therapeutics, Inc..

Action: elected
Role: Director

Exact text from the filing

On October 30, 2024, the Board of Directors (the “Board”) of MiNK Therapeutics Inc., ("MiNK") elected Dr. Robert Kadlec to become a Class II director of MiNK with an initial term that expires at MiNK's annual meeting of stockholders in 2026.

View on SEC.gov

MiNK Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-119270

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.